Literature DB >> 18508107

Arylstibonic acids: novel inhibitors and activators of human topoisomerase IB.

Hyeongnam Kim1, John H Cardellina, Rhone Akee, James J Champoux, James T Stivers.   

Abstract

Human topoisomerase IB (hTopo) forms a covalent phosphotyrosyl linkage with the DNA backbone, and controls genomic DNA topology by relaxing DNA supercoils during the processes of DNA replication, transcription, chromosome condensation and decondensation. The essential role of hTopo in these processes has made it a preeminent anticancer drug target. We have screened a small library of arylstibonic acids for their effects on plasmid supercoil relaxation catalyzed by hTopo. Despite the similar structures of the library compounds, some compounds were found to be effective competitive inhibitors, and others, nonessential activators. Some arylstibonic acids show selectivity in their action against hTopo and the related enzyme from poxvirus (vTopo). Structure-activity relationships and structural modeling suggest that competitive inhibition may result from positioning of the negatively charged stibonic acid and carboxylate groups of the inhibitors into DNA phosphate binding pockets on hTopo. The hTopo activators act by a surprising allosteric mechanism without interfering with DNA binding or binding of the widely used hTopo poison camptothecin. Arylstibonic acid competitive inhibitors may become useful small molecules for elucidating the cellular functions of hTopo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508107      PMCID: PMC2574574          DOI: 10.1016/j.bioorg.2008.04.001

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  19 in total

1.  Topoisomerase I inhibitors: selectivity and cellular resistance.

Authors:  Yves Pommier; Philippe Pourquier; Yoshimasa Urasaki; Jiaxi Wu; Gary S. Laco
Journal:  Drug Resist Updat       Date:  1999-10       Impact factor: 18.500

2.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

3.  Novel and specific inhibitors of a poxvirus type I topoisomerase.

Authors:  Alexis Bond; Zachary Reichert; James T Stivers
Journal:  Mol Pharmacol       Date:  2005-11-02       Impact factor: 4.436

Review 4.  [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].

Authors:  P Pourquier; Y Pommier
Journal:  Bull Cancer       Date:  1998-12       Impact factor: 1.276

5.  A model for the mechanism of human topoisomerase I.

Authors:  L Stewart; M R Redinbo; X Qiu; W G Hol; J J Champoux
Journal:  Science       Date:  1998-03-06       Impact factor: 47.728

Review 6.  Topoisomerase I inhibitors: camptothecins and beyond.

Authors:  Yves Pommier
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

7.  Ribonuclease activity of vaccinia DNA topoisomerase IB: kinetic and high-throughput inhibition studies using a robust continuous fluorescence assay.

Authors:  Keehwan Kwon; Rajesh Nagarajan; James T Stivers
Journal:  Biochemistry       Date:  2004-11-30       Impact factor: 3.162

8.  Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses.

Authors:  Ze-Hong Miao; Audrey Player; Uma Shankavaram; Yong-Hong Wang; Drazen B Zimonjic; Philip L Lorenzi; Zhi-Yong Liao; Hong Liu; Tsutomu Shimura; Hong-Liang Zhang; Ling-Hua Meng; Yong-Wei Zhang; Ernest S Kawasaki; Nicholas C Popescu; Mirit I Aladjem; David J Goldstein; John N Weinstein; Yves Pommier
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

9.  DNA topoisomerase I is essential in Drosophila melanogaster.

Authors:  M P Lee; S D Brown; A Chen; T S Hsieh
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

10.  Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids.

Authors:  Lauren A Seiple; John H Cardellina; Rhone Akee; James T Stivers
Journal:  Mol Pharmacol       Date:  2007-11-27       Impact factor: 4.436

View more
  7 in total

1.  12 Arylstibonic acids that inhibit the DNA binding of five B-ZIP dimers.

Authors:  Vikas Rishi; Won-Jun Oh; Sarah L Heyerdahl; Jianfei Zhao; Dominic Scudiero; Robert H Shoemaker; Charles Vinson
Journal:  J Struct Biol       Date:  2010-02-20       Impact factor: 2.867

2.  Arylstibonic acids are potent and isoform-selective inhibitors of Cdc25a and Cdc25b phosphatases.

Authors:  Lok Hang Mak; Jessica Knott; Katherine A Scott; Claire Scott; Gillian F Whyte; Yu Ye; David J Mann; Oscar Ces; James Stivers; Rudiger Woscholski
Journal:  Bioorg Med Chem       Date:  2012-05-24       Impact factor: 3.641

Review 3.  Base excision repair: contribution to tumorigenesis and target in anticancer treatment paradigms.

Authors:  J L Illuzzi; D M Wilson
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 4.  Small molecule inhibitors of DNA repair nuclease activities of APE1.

Authors:  David M Wilson; Anton Simeonov
Journal:  Cell Mol Life Sci       Date:  2010-08-31       Impact factor: 9.261

5.  Inhibition of Yersinia pestis DNA adenine methyltransferase in vitro by a stibonic acid compound: identification of a potential novel class of antimicrobial agents.

Authors:  J C McKelvie; M I Richards; J E Harmer; T S Milne; P L Roach; P C F Oyston
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

6.  P6981, an arylstibonic acid, is a novel low nanomolar inhibitor of cAMP response element-binding protein binding to DNA.

Authors:  Jianfei Zhao; Jason R Stagno; Lyuba Varticovski; Eric Nimako; Vikas Rishi; Kathy McKinnon; Rhone Akee; Robert H Shoemaker; Xinhua Ji; Charles Vinson
Journal:  Mol Pharmacol       Date:  2012-07-31       Impact factor: 4.436

7.  Cross-Species Complementation of Nonessential Yeast Genes Establishes Platforms for Testing Inhibitors of Human Proteins.

Authors:  Akil Hamza; Maureen R M Driessen; Erik Tammpere; Nigel J O'Neil; Philip Hieter
Journal:  Genetics       Date:  2020-01-14       Impact factor: 4.562

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.